EyewireTV
October 19, 2022
October 19, 2022
CLINICAL TRIAL DOWNLOAD: Data From the Phase 2b Trial of OPT-302 October 1, 2022
EyeWorld Onsite
September 30, 2022
September 30, 2022
Opthea CEO discusses updates on OPT-302 for treatment of wet AMD
September 30, 2022
August 16, 2022
December 19, 2019
August 8, 2019
Biotech Daily: Doctor Boreham’s Crucible
August 16, 2019
June 14, 2019
May 16, 2019
small cap companies
March 15, 2019
March 15, 2019
The Australian Financial Review
February 27, 2019
February 27, 2019
Top Six Stock Picks 2019
December 21, 2018
December 21, 2018
Opthea’s Strategy to Build Value for OPT-302
December 03, 2018
December 03, 2018
ASX, The CEO Sessions – Opthea Limited
February 16, 2016
February 16, 2016
Bell Potter – Top 3 Stocks in Healthcare & Biotech for 2016 – Opthea
January 08, 2016
January 08, 2016
Bioshares Report
February 13, 2015
February 13, 2015
Eureka Report – Opthea’s interview with Alan Kohler
December 02, 2015
December 02, 2015
Merger Market: Circadian Technologies
July 06, 2015
July 06, 2015
CommSec Executive Series: CEO Circadian Technologies Ltd
June 17, 2015
June 17, 2015
Channel 9 News Wet AMD & OPT-302 Feature Story
March 20, 2015
March 20, 2015
Biotech Daily CEO Interview
March 06, 2015
March 06, 2015
OzEquities Newsletter
November 14, 2014
November 14, 2014
Bioshares Report
November 14, 2014
November 14, 2014
Market Analysis Report – May 12 2014
May 12, 2014
May 12, 2014
Channel 9 News LAM feature story
April 02, 2012
April 02, 2012